Humana (HUM): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Humana ( HUM) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.1%. By the end of trading, Humana rose $1.26 (1.2%) to $105.25 on average volume. Throughout the day, 980,926 shares of Humana exchanged hands as compared to its average daily volume of 1,239,600 shares. The stock ranged in a price between $103.81-$105.80 after having opened the day at $104.01 as compared to the previous trading day's close of $103.99. Other companies within the Health Care sector that increased today were: Biostar Pharmaceuticals ( BSPM), up 38.1%, Vision-Sciences Inc (DE ( VSCI), up 25.2%, XOMA ( XOMA), up 22.2% and Dynatronics Corporation ( DYNT), up 19.8%.

Humana Inc., a health care company, offers a range of insurance products, and health and wellness services that incorporate an integrated approach to lifelong well-being. The company operates in three segments: Retail, Employer Group, and Healthcare Services. Humana has a market cap of $16.2 billion and is part of the health services industry. The company has a P/E ratio of 11.4, below the S&P 500 P/E ratio of 17.7. Shares are up 51.2% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Humana a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Humana as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Mast Therapeutics ( MSTX), down 38.9%, Aastrom Biosciences ( ASTM), down 11.5%, Pernix Therapeutics Holdings ( PTX), down 9.8% and Orexigen Therapeutics ( OREX), down 9.5% , were all laggards within the health care sector with Laboratory Corporation of America Holdings ( LH) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Apple Is the Tom Brady of Stocks: Cramer's 'Mad Money' Recap (Thursday 8/31/17)

Boeing, Pure Storage, Activision Blizzard: 'Mad Money' Lightning Round

The Makings of Another Huge Rebound?

Healthcare Management Stocks Look Too Pricey for Activists

Tenet Dives After Worse Than Expected Quarter Leads to Lower 2017 Outlook